Cargando…
Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast
Five of 43 patients (11.6%) with ductal carcinoma in situ of the breast presented with p53 autoantibodies at diagnosis. Three seropositive patients demonstrated tumour sizes of ≤ 5 mm. There was no association of p53 autoantibody status with age, clinical presentation, histological subtype, tumour s...
Autores principales: | Regele, S, Kohlberger, P, Vogl, F D, Böhm, W, Kreienberg, R, Runnebaum, I B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362899/ https://www.ncbi.nlm.nih.gov/pubmed/10574259 http://dx.doi.org/10.1038/sj.bjc.6690751 |
Ejemplares similares
-
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass
por: Vogl, F D, et al.
Publicado: (2000) -
C-erbB-2 overexpression in primary breast cancer: relationship to clinical and histopathological parameters of patients with breast cancer
por: Regele, S, et al.
Publicado: (2001) -
p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma.
por: Runnebaum, I. B., et al.
Publicado: (1996) -
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
por: Wang-Gohrke, S, et al.
Publicado: (1999) -
Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast
por: He, Xiaofang, et al.
Publicado: (2017)